Full-Time

Document Control & Quality Systems Administrator

Noctrix Health

Noctrix Health

51-200 employees

Prescription wearable neuromodulation for RLS.

Compensation Overview

$120k - $140k/yr

+ Annual bonus

Pleasanton, CA, USA

Hybrid

Hybrid work is available at the Pleasanton headquarters, or the role may be performed remotely.

Bachelor's, Associate's

Category
IT & Security (1)
Required Skills
Microsoft Office

Get referred to Noctrix Health

See people who can refer or advise you

Requirements
  • An Associate’s or Bachelor’s degree in a scientific, technical, quality, business administration, or related discipline.
  • At least 3 years of experience in document control, Quality Systems administration, training administration, or Quality Assurance within a medical device, biotechnology, pharmaceutical, or other regulated industry.
  • Demonstrated experience administering document control systems, training systems, electronic Quality Management System platforms, and Quality System records.
  • Working knowledge of FDA Quality System requirements, ISO 13485, document control principles, electronic records, training management, and record retention requirements.
  • Experience supporting Quality System processes such as change control, corrective and preventive action, nonconformances, supplier management, audits, inspections, or calibration programs.
  • Experience maintaining accurate, traceable, and inspection-ready Quality System documentation.
  • Proficiency with Microsoft Office applications and electronic Quality Management Systems.
  • Ability to independently manage multiple priorities and deadlines.
  • Strong attention to detail and commitment to documentation accuracy and data integrity.
  • Strong written and verbal communication skills.
  • Ability to work independently while collaborating across multiple functions.
Responsibilities
  • Serve as the primary administrator for document control and the electronic Quality Management System, ensuring compliance with internal procedures and applicable regulatory requirements.
  • Manage the complete lifecycle of controlled documents, including formatting, routing, review, approval, issuance, revision, obsolescence, archival, and retention.
  • Administer electronic Quality Management System workflows, user access, system data integrity, and routine system maintenance.
  • Perform and document electronic Quality Management System validation activities associated with changes to document control templates, workflows, and applicable system functionality.
  • Develop, maintain, and improve document control procedures, templates, workflows, and related Quality System documentation.
  • Administer the company’s quality training program, including training assignments, completion tracking, training matrices, and electronic training records.
  • Monitor training compliance and partner with department leaders to ensure required training is completed accurately and on time.
  • Provide training and ongoing user support for document control, training, and electronic Quality Management System processes.
  • Maintain calibration records and coordinate calibration activities with approved service providers.
  • Administer the Approved Supplier List and support the Supplier Management Program, including supplier records, qualification status, reassessments, audit schedules, and quality agreements.
  • Manage Quality System records and archives in accordance with company procedures and record-retention requirements.
  • Review Lot History Records for completeness and compliance with Good Documentation Practices, resolve documentation issues, and support finished-goods release to inventory.
  • Support Quality System processes including change control, Management Review, Design Reviews, corrective and preventive action, nonconformances, complaints, supplier management, audits, inspections, and validation activities.
  • Prepare, organize, and maintain inspection-ready records for internal audits, supplier audits, regulatory inspections, and certification audits.
  • Partner with Quality, Regulatory Affairs, Clinical Affairs, Engineering, Operations, and Manufacturing to ensure timely execution of Quality System activities.
  • Identify and implement opportunities to improve document control and Quality System administration for efficiency, consistency, data integrity, and compliance.
  • Provide additional Quality Systems and operational support as organizational needs evolve.
Desired Qualifications
  • Experience within an FDA-regulated medical device organization.
  • Experience with Arena or a comparable electronic Quality Management System.
  • Experience serving as an electronic Quality Management System administrator, system owner, or power user.
  • Experience with electronic Quality Management System validation, system configuration, workflow changes, or system enhancements.
  • Familiarity with FDA 21 CFR Part 820, 21 CFR Part 11, ISO 13485, and Good Documentation Practices.
  • Experience supporting FDA inspections, ISO certification audits, or other regulatory audits.
  • Experience with supplier administration, calibration programs, and manufacturing quality records.
  • Experience reviewing Lot History Records and supporting finished-goods release.

Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.

Company Size

51-200

Company Stage

Acquired

Total Funding

$90.5M

Headquarters

Pleasanton, California

Founded

2018

Get referred to Noctrix Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Noctrix reported about $24 million annual run-rate revenue before closing, already commercializing.
  • CMS issued dedicated HCPCS codes and payment in 2024, reducing patient access friction.
  • ResMed can cross-sell Nidra through existing sleep clinics, HME partners, and international distribution.

What critics are saying

  • ResMed must integrate Noctrix by late 2026 while preserving sales momentum and reimbursement.
  • RLS prescriptions depend on sleep physicians and HMEs; coverage changes would choke adoption quickly.
  • If Nidra stalls below ResMed's expectations, the asset becomes a small, deprioritized portfolio experiment.

What makes Noctrix Health unique

  • Nidra is FDA De Novo-cleared, drug-free TOMAC for medication-refractory RLS.
  • AASM guidelines recognized peroneal nerve stimulation in 2024, validating Noctrix's mechanism.
  • ResMed completed the $340 million acquisition on June 1, 2026, giving channel reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

2%

2 year growth

0%
Sleep Review Magazine
May 5th, 2026
Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker.

Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker. Resmed will acquire the manufacturer of an fda-cleared nerve stimulation device for refractory RLS, a move that leverages its existing sleep physician and home medical equipment channels. Key takeaways: * Resmed has signed an agreement to acquire Noctrix Health, maker of the Nidra device, for a purchase price of $340 million. * The acquisition targets the estimated 7% of adults globally affected by RLS, a population with meaningful overlap with obstructive sleep apnea. * The transaction is expected to close around June 1, 2026, with revenue to be reported within Resmed's Americas Devices category. Resmed has signed a $340 million agreement to acquire Noctrix Health, a medical device company with an FDA de novo classified product indicated for the treatment of refractory moderate-to-severe restless legs syndrome (RLS). The flagship product, Nidra, is a noninvasive nerve stimulation device. The acquisition marks Resmed's expansion into adjacent sleep health markets, targeting what is considered the third-most-prevalent sleep disorder after obstructive sleep apnea (OSA) and insomnia. RLS affects approximately 7% of adults globally, including around 17 million people in the US, and has a meaningful overlap with OSA. "RLS treatments from Noctrix are noninvasive, clinically proven, and drug-free, just like our CPAP/APAP and bilevel therapies," said Michael Farrell, CEO and chairman of the board at Resmed, during the company's third-quarter earnings call. Resmed, which has been an investor in Noctrix since 2024, plans to leverage its established market access to scale the therapy. Prescriptions for the device are written predominantly by sleep physicians and flow through the same home medical equipment (HME) and durable medical equipment (DME) delivery channels where Resmed currently holds a leading market share. "The reach of our Resmed brand among sleep physicians and HME providers as well as our national and international distribution channel strength makes us the best owner of this scarce asset," Farrell said. The transaction is targeted to close on or around June 1, 2026. Noctrix currently has an annual run rate revenue of approximately $24 million, which Resmed notes is growing at a faster rate and operating at a higher gross margin than Resmed's core business. Once closed, Noctrix's financials will be reported within Resmed's Americas Devices category. The acquisition is expected to result in an approximate $0.02 reduction in non-GAAP earnings per share for the fourth quarter of fiscal year 2026 as Resmed continues to invest in research and development and sales and marketing for the new asset.

Simply Wall St
May 1st, 2026
ResMed names new CFO and acquires Noctrix Health to expand into neurology

ResMed has appointed Aaron Bloomer as chief financial officer, replacing retiring CFO Brett Sandercock, and agreed to acquire Noctrix Health, a medical device company specialising in restless leg syndrome treatments. The moves mark a strategic shift for ResMed, which is primarily known for sleep apnoea devices and related software. The Noctrix acquisition expands the company's portfolio into neurological conditions affecting sleep quality, broadening its clinical scope beyond traditional respiratory care. Investors will be watching how ResMed balances capital allocation between its core sleep apnoea business and new neurology-related devices. Integration risks around Noctrix, including regulatory and reimbursement hurdles, remain key factors to monitor. At $213.81, ResMed shares trade approximately 26% below the analyst target of $288.21.

Michael West Media
May 1st, 2026
Snoring leader buys restless leg syndrome device maker - Michael West

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the third-biggest sleep disorder.

FinSMEs
Sep 2nd, 2025
Noctrix Health Raises Up To $33.5M in Debt and Equity Funding

Noctrix Health raises up to $33.5M in debt and equity funding.

FinancialContent
Aug 29th, 2025
Noctrix Health Raises $33.5M for RLS Therapy

Noctrix Health has raised $33.5 million to accelerate the U.S. commercialization of its Nidra® TOMAC therapy for Restless Legs Syndrome (RLS). The funding includes contributions from Blue Venture Fund, Sandbox Clinical Ventures, and a debt facility from Bridge Bank. The company has also expanded its leadership team, appointing Ivan Lubogo as Chief Commercial Officer and promoting Jonathan Charlesworth, Ph.D., to Chief Scientific Officer. Mark Verratti joins the Board of Directors.